CAI Company Profile and Key Details

CAI has shown mixed momentum, gaining 2.62% over the past week and -16.6% over the past quarter, though year-to-date performance is down -2.63%. Short-term trend indicators are bullishly aligned (SMA20 -9.0%, SMA50 -22.14%, SMA200 -32.53%). The stock’s 14-day RSI is 34.48 (weak momentum), while the ATR of 1.28 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -54.73% below its high and over 12.19% above its low. Average 10-day trading volume of 2.96 million shares is slightly above the 3-month average of 2.35 million, indicating heightened recent market interest.

Caris Life Sciences, Inc. has 281.27 million shares outstanding. The public float is 91.92 million shares, elevated short interest at 1.20% of float. This equals 1.73 million shares. The short ratio is 2.51 days. Institutional investors hold 90.37% of the float. Insiders own 49.02%. Spetzler David Baxley holds 460.78 thousand shares, Power Luke Thomas has 99.57 thousand shares and Denton John Russel has 9.18 thousand shares. Over the past six months, insider transactions show net buying. They sold 1.40 thousand shares across 1 transactions.

Caris Life Sciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$13.78. This means the shares are trading below this model’s fair value.

Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 6 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $45.00 to $26.00. The high target offers 132.2% upside. The low target suggests 34.16% downside. The mean target is $33.80. This offers 74.41% upside. Caris Life Sciences, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -200.0%. The prior quarter beat by 157.14%. Over the last six quarters, Apple has recorded several small beats. These include 157.14% in August 12, 2025.

Caris Life Sciences, Inc. (NASDAQ:CAI) closed at $19.22 USD, losing -$0.64 (-3.22%) from the previous close of $19.86. The stock is currently mid-range between its 52-week high and low $17.15 and $42.50. With a market capitalization of about $5.42 billion, Caris Life Sciences, Inc. is classified as a mid-cap and shows market-like volatility (beta ~1.09). Key stats such as the average daily volume over the past year has been around 2.38 million shares, in line with its 52-week average. Headquartered in Irving, TX, Caris Life Sciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David Dean Halbert, the company employs approximately 1,769 people and listed since June 18, 2025. Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.

Caris Life Sciences, Inc. trades at a P/E ratio of -60.75, slightly below the S&P 500 average, with a price-to-sales ratio of 6.79 and a price-to-book ratio of 56.61 reflecting a rich premium to book value. The P/FCF stands at 167.79, also above market averages. Compared to sector medians, Caris Life Sciences, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that Caris Life Sciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -10.17%, with price expected at $17.41 by March 17, 2026, within a range of $16.28 to $18.60 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by June 01, 2026, with a range of $0.00 to $0.00. 1-Year Outlook: Projected loss of -96.85%, with price at $0.61 by March 03, 2027, within a range of $0.00 to $1.43.

Caris Life Sciences, Inc. (NASDAQ:CAI) shares are flat -2.63% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Caris Life Sciences, Inc. trading at a premium to the broader market with a P/E of -60.75. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $33.80, suggesting 74.41% upside. Our AI forecast model points to short-term weakness (-10.17% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-96.85% over one year), with expected trading ranges indicating moderate volatility.